Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM4KDYJ)

• Drug Name: Nortriptyline Drug Info
• Synonyms: Acetexa; Allegron; Altilev; Ateben; Avantyl; Aventyl; Demethylamitriptylene; Demethylamitriptyline; Demethylamitryptyline; Desitriptilina; Desitriptyline; Desmethylamitriptylin; Desmethylamitriptyline; Lumbeck; Noramitriptyline; Noritren; Nortrilen; Nortriptilina; Nortriptylinum; Nortryptiline; Nortryptyline; Pamelor; Psychostyl; Sensaval; Sesaval; Vividyl; AVENTYL HCL; Nortriptilina [DCIT]; Nortriptylene hydrochloride; Pamelor hydrochloride; Sensival Ventyl; NCI169453; Allegron (TN); Aventyl (TN); Norpress (TN); Nortrilen (TN); Nortriptyline (INN); Nortriptyline [INN:BAN]; Nortriptylinum [INN-Latin]; Pamelor (TN); Sensoval (TN); N-Methyl-3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)propylamin; (2)10,11-Dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-.delta.5.gamma.-propylamine; 10,11-Dihydro-5-(3-methylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptene; 10,11-Dihydro-N-methyl-5H-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine; 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methylpropylamine; 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine; 5-(3-(Methylamino)propylidene)dibenzo(a,e)cyclohepta(1,5)diene; 5-(3-Methylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(alpha-Methylaminopropylidene)dibenzo(a,d)cyclohepta(1,4)diene
• Therapeutic Class: Antidepressants
• Cross-matching ID:
  PubChem CID: 4543
  ChEBI ID: CHEMBL445
  CAS Number: CAS 72-69-5
  TTD Drug ID: D04WFD
  VARIDT Drug ID: DR00398
  INTEDE Drug ID: DR1181
  ACDINA Drug ID: D00480

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Lysosome	2.49	0.00e+0	115/128 (89.84%)	NPC2;ACP5;NEU1;...
Steroid biosynthesis	2.40	0.00e+0	19/20 (95%)	MSMO1;SQLE;DHCR24;...
Terpenoid backbone biosynthesis	2.37	0.00e+0	18/22 (81.82%)	HMGCS1;ACAT2;IDI1;...
Vibrio cholerae infection	2.16	0.00e+0	44/50 (88%)	ATP6V0E2;PRKCA;ATP6AP1;...
Amino sugar and nucleotide sugar metabolism	2.00	1.65e-3	38/48 (79.17%)	HEXB;NPL;NAGK;...
Synthesis and degradation of ketone bodies	1.95	1.38e-3	9/10 (90%)	HMGCS1;ACAT2;HMGCL;...
Glycosaminoglycan degradation	1.88	2.36e-3	19/19 (100%)	HEXB;IDS;HGSNAT;...
Synaptic vesicle cycle	1.84	7.23e-3	63/78 (80.77%)	ATP6V0E2;STXBP1;ATP6V1D;...
Primary bile acid biosynthesis	1.82	1.10e-2	15/17 (88.24%)	CYP27A1;AMACR;BAAT;...
Butanoate metabolism	1.82	9.91e-3	23/28 (82.14%)	HMGCS1;ACAT2;HMGCL;...
Pentose phosphate pathway	1.77	1.95e-2	25/30 (83.33%)	ALDOC;TALDO1;FBP1;...
Mucin type O-glycan biosynthesis	1.75	2.13e-2	20/36 (55.56%)	ST6GALNAC2;GALNT1;GALNT3;...
Biosynthesis of unsaturated fatty acids	1.74	2.16e-2	21/27 (77.78%)	SCD;FADS2;FADS1;...
Phagosome	1.74	2.01e-2	118/152 (77.63%)	CYBB;FCGR2C;COLEC12;...
B cell receptor signaling pathway	1.70	3.03e-2	71/81 (87.65%)	IFITM1;FCGR2B;BLNK;...
mTOR signaling pathway	1.69	3.05e-2	114/154 (74.03%)	LPIN1;SLC7A5;PRKCA;...
Staphylococcus aureus infection	1.67	3.84e-2	72/95 (75.79%)	FCGR2C;FCGR2A;DEFB1;...
Salivary secretion	1.66	4.04e-2	76/93 (81.72%)	CST1;CST3;PRKCA;...
Osteoclast differentiation	1.64	4.87e-2	117/127 (92.13%)	ACP5;FCGR2C;FCGR2A;...
Huntington disease	-1.73	4.60e-2	233/306 (76.14%)	HTT;BDNF;TBP;...
DNA replication	-1.83	2.47e-2	34/36 (94.44%)	POLD3;RPA4;SSBP1;...
Prion disease	-1.87	1.70e-2	209/273 (76.56%)	ITPR3;C8B;EIF2S1;...
Viral myocarditis	-1.89	1.59e-2	53/60 (88.33%)	BID;HLA-B;EIF4G1;...
Legionellosis	-1.91	1.23e-2	51/57 (89.47%)	HSPD1;NFKBIA;BCL2L13;...
Parkinson disease	-1.94	9.88e-3	176/249 (70.68%)	ITPR3;EIF2S1;KLC2;...
Ribosome	-2.01	6.17e-3	113/158 (71.52%)	RPL7A;RPS16;RPS15;...
Non-alcoholic fatty liver disease	-2.02	8.23e-3	126/155 (81.29%)	NDUFV2;COX7C;PRKAA1;...
Proteasome	-2.09	0.00e+0	44/46 (95.65%)	PSMC1;PSMB1;PSMA2;...
Ribosome biogenesis in eukaryotes	-2.11	0.00e+0	52/108 (48.15%)	GAR1;RPP40;DKC1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 2.22uM	24H	Hide ▲

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.04uM - 10uM	24H	Show ▼